Hypokalemia, Its Contributing Factors and Renal Outcomes in Patients with Chronic Kidney Disease

Background In the chronic kidney disease (CKD) population, the impact of serum potassium (sK) on renal outcomes has been controversial. Moreover, the reasons for the potential prognostic value of hypokalemia have not been elucidated. Design, Participants & Measurements 2500 participants with CKD stage 1–4 in the Integrated CKD care program Kaohsiung for delaying Dialysis (ICKD) prospective observational study were analyzed and followed up for 2.7 years. Generalized additive model was fitted to determine the cutpoints and the U-shape association between sK and end-stage renal disease (ESRD). sK was classified into five groups with the cutpoints of 3.5, 4, 4.5 and 5 mEq/L. Cox proportional hazard regression models predicting the outcomes were used. Results The mean age was 62.4 years, mean sK level was 4.2±0.5 mEq/L and average eGFR was 40.6 ml/min per 1.73 m2. Female vs male, diuretic use vs. non-use, hypertension, higher eGFR, bicarbonate, CRP and hemoglobin levels significantly correlated with hypokalemia. In patients with lower sK, nephrotic range proteinuria, and hypoalbuminemia were more prevalent but the use of RAS (renin-angiotensin system) inhibitors was less frequent. Hypokalemia was significantly associated with ESRD with hazard ratios (HRs) of 1.82 (95% CI, 1.03–3.22) in sK <3.5mEq/L and 1.67 (95% CI,1.19–2.35) in sK = 3.5–4 mEq/L, respectively, compared with sK = 4.5–5 mEq/L. Hyperkalemia defined as sK >5 mEq/L conferred 1.6-fold (95% CI,1.09–2.34) increased risk of ESRD compared with sK = 4.5–5 mEq/L. Hypokalemia was also associated with rapid decline of renal function defined as eGFR slope below 20% of the distribution range. Conclusion In conclusion, both hypokalemia and hyperkalemia are associated with increased risk of ESRD in CKD population. Hypokalemia is related to increased use of diuretics, decreased use of RAS blockade and malnutrition, all of which may impose additive deleterious effects on renal outcomes.

[1]  N. Madias,et al.  Sodium and potassium in the pathogenesis of hypertension. , 2007, The New England journal of medicine.

[2]  G. Bakris,et al.  Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease: Findings From Propensity-Matched Studies , 2010, Circulation. Heart failure.

[3]  M. Zhan,et al.  The frequency of hyperkalemia and its significance in chronic kidney disease. , 2009, Archives of internal medicine.

[4]  S. Suga,et al.  Chronic potassium depletion induces renal injury, salt sensitivity, and hypertension in young rats. , 2001, Kidney international.

[5]  N. Powe,et al.  Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  A. Greenberg,et al.  Diuretic complications. , 2000, The American journal of the medical sciences.

[7]  A. Greenberg.  Original articleDiuretic Complications , 2000 .

[8]  B. Pitt,et al.  Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[9]  Takahiko Nakagawa,et al.  Hypokalemic nephropathy is associated with impaired angiogenesis. , 2008, Journal of the American Society of Nephrology : JASN.

[10]  T. Hostetter,et al.  Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury. , 1987, The Journal of clinical investigation.

[11]  C. Wild,et al.  Vector Generalized Additive Models , 1996 .

[12]  Ping Zhang,et al.  Renal inflammation is modulated by potassium in chronic kidney disease: possible role of Smad7. , 2007, AJP - Renal Physiology.

[13]  B. Baudin.  Angiotensin I-Converting Enzyme Gene Polymorphism and Drug Response , 2000, Clinical chemistry and laboratory medicine.

[14]  R. Foley,et al.  Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. , 1996, Journal of the American Society of Nephrology : JASN.

[15]  S. Greenland,et al.  Serum and dialysate potassium concentrations and survival in hemodialysis patients. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[16]  G. Remuzzi,et al.  Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. , 2005, Journal of the American Society of Nephrology : JASN.

[17]  B. Brenner,et al.  Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial , 2011, Diabetologia.

[18]  B. Brenner,et al.  Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. , 2006, Kidney international.

[19]  H. T. Milhorn.  Diuretic induced hypokalemia. , 1983, The Journal of family practice.

[20]  J. Lunceford,et al.  ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. , 2008, Journal of the American Society of Nephrology : JASN.

[21]  K P Offord,et al.  Association of hypokalemia, aldosteronism, and renal cysts. , 1990, The New England journal of medicine.

[22]  T. Pratipanawatr,et al.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia , 2008, Current opinion in nephrology and hypertension.

[23]  M. Gheorghiade,et al.  Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. , 2006, European heart journal.

[24]  T. MacDonald,et al.  Review of aldosterone- and angiotensin II-induced target organ damage and prevention. , 2004, Cardiovascular research.

[25]  J. Craig,et al.  Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. , 2006, The Cochrane database of systematic reviews.

[26]  C. Wingo,et al.  Hypokalemia--consequences, causes, and correction. , 1997, Journal of the American Society of Nephrology : JASN.

[27]  Olivier Moranne,et al.  Timing of onset of CKD-related metabolic complications. , 2009, Journal of the American Society of Nephrology : JASN.

[28]  M Epstein,et al.  Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift , 2001, Journal of hypertension.

[29]  B. Croker,et al.  Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia. , 2007, Kidney international.

[30]  P. Aljama,et al.  C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients. , 2007, Clinical nephrology.

[31]  Y. G. Kim,et al.  Hypokalemia induces renal injury and alterations in vasoactive mediators that favor salt sensitivity. , 2001, American journal of physiology. Renal physiology.

[32]  G. Beck,et al.  C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. , 2005, Kidney international.

[33]  G. Giebisch,et al.  New aspects of renal potassium transport , 2003, Pflügers Archiv.

[34]  P. Palevsky,et al.  Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. , 1998, Archives of internal medicine.

[35]  G. Remuzzi,et al.  Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[36]  Y. Ubara,et al.  Analysis of factors causing hyperkalemia. , 2007, Internal medicine.

[37]  P. Sarafidis,et al.  Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[38]  Akram Khan,et al.  Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors Analysis , 2008, The American journal of the medical sciences.

[39]  B. Davis,et al.  Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial , 2012, Hypertension.

[40]  M. Bazzocchi,et al.  Renal cysts and hypokalemia in primary aldosteronism: results of long-term follow-up after treatment , 2007, Journal of hypertension.

[41]  S. Suga,et al.  Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency. , 2002, Kidney international.

[42]  Kamyar Kalantar-Zadeh,et al.  Association of Hypo- and Hyperkalemia with Disease Progression and Mortality in Males with Chronic Kidney Disease: The Role of Race , 2011, Nephron Clinical Practice.

[43]  N M Thomson,et al.  Hypokalaemia-induced acute renal failure. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.